Orodispersible dosage unit containing an estetrol component
An orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg is disclosed. The dosage unit comprises (a) 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and (b) 75-99.9 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage unit comprises at least 100 μg of the estetrol component and can be obtained by a process that comprises compressing a dry blend of estetrol particles and one or more pharmaceutically acceptable excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration.
1. A process of preparing an estetrol orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, the dosage unit comprising:
(a) 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters, and combinations thereof; and
(b) 75-99.9 wt. % of one or more pharmaceutically acceptable excipients;
wherein the solid dosage unit contains at least 100 μg of the estetrol component and disintegrates within less than 5 minutes when subjected to disintegration testing in accordance with USP <701>(“Disintegration”) using water as the disintegration medium, the process comprising:
(i) providing estetrol particles having a volume median diameter between 2 μm to 50 μm and containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof;
(ii) mixing 1 part by weight of the estetrol particles with 2-1,000 parts by weight of one or more pharmaceutically acceptable excipients to obtain a dry blend; and
(iii) compressing the dry blend into a solid dosage unit.
2. The process according to claim 1 , wherein the process does not comprise addition of liquid solvent during or after the combining of the estetrol particles and the one or more pharmaceutically acceptable excipients.
3. The process according to claim 1 , wherein the solid dosage unit is formed by direct compression.
4. The process according to claim 1 , wherein the dosage unit has a weight between 40 and 500 mg.
5. The process according to claim 1 , wherein the dosage unit contains 0.5-25 wt. % of the estetrol component.
6. The process according to claim 1 , wherein the dosage unit contains 0.3-100 mg of the estetrol component.
7. The process according to claim 1 , wherein the estetrol component is estetrol.
8. The process according to claim 1 , wherein the estetrol particles have a volume median diameter of 3-35 μm.
9. The process according to claim 1 , wherein the dosage unit contains 50-99.5 wt. % of filler selected from maltose, fructose, sucrose, lactose, glucose, galactose, trehalose, xylitol, sorbitol, erythritol, maltitol, mannitol, isomalt, microcrystalline cellulose, calcium salts, and combinations of any thereof.
10. The process according to claim 1 , wherein the dosage unit contains 30-99.5 wt. % of filler selected from lactose, xylitol, sorbitol, erythritol, mannitol, microcrystalline cellulose, and combinations of any thereof.
11. The process according to claim 1 , wherein the dosage unit contains 30-90 wt. % of sugar alcohol selected from mannitol, xylitol, and combinations thereof.
12. The process according to claim 1 , wherein the dosage unit contains 0.1-20 wt. % of a disintegrating agent selected from modified starches, crosslinked polyvinyl pyrrolidone, crosslinked carmellose, and combinations of any thereof.
13. The process according to claim 1 , wherein the dosage unit contains 5-40 wt. % of microcrystalline cellulose.
14. The process according to claim 1 , wherein the dosage unit contains 0.1-2 wt. % of lubricant selected from sodium stearyl fumarate, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, polyethylene glycol, calcium stearate, and combinations of any thereof.